PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers.

PD-L1 colorectal cancer mismatch repair prognosis

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
26 Jan 2021
Historique:
received: 23 12 2020
revised: 19 01 2021
accepted: 24 01 2021
entrez: 3 2 2021
pubmed: 4 2 2021
medline: 4 2 2021
Statut: epublish

Résumé

Several clinical trials are investigating the use of immune-targeted therapy with Programmed death ligand-1 (PD-L1) inhibitors for colorectal cancer (CRC), with promising results for patients with mismatch repair (MMR) deficiency or metastatic CRC. However, the prognostic significance of PD-L1 expression in CRC is controversial and such data are lacking in CRC from Middle Eastern ethnicity. We carried out this large retrospective study to investigate the prognostic and clinico-pathological impact of PD-L1 expression in Middle Eastern CRC using immunohistochemistry. A total of 1148 CRC were analyzed for PD-L1 expression. High PD-L1 expression was noted in 37.3% (428/1148) cases and was correlated with aggressive clinico-pathological features such as high malignancy grade (

Identifiants

pubmed: 33530623
pii: jpm11020073
doi: 10.3390/jpm11020073
pmc: PMC7911042
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Anticancer Res. 2015 Oct;35(10):5369-76
pubmed: 26408698
Oncotarget. 2015 Oct 20;6(32):33972-81
pubmed: 26378017
Oncol Lett. 2019 Nov;18(5):5399-5407
pubmed: 31612048
Front Immunol. 2019 Oct 04;10:2298
pubmed: 31636634
Br J Cancer. 2017 Jun 27;117(1):1-7
pubmed: 28524159
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2017 Jun 27;8(26):41932-41946
pubmed: 28410210
Cells. 2020 Mar 04;9(3):
pubmed: 32143413
Mod Pathol. 2016 Sep;29(9):1104-12
pubmed: 27198569
J Clin Oncol. 2020 Jan 20;38(3):214-222
pubmed: 31765263
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Cancer. 2018 Oct 21;9(23):4325-4333
pubmed: 30519336
Expert Rev Anticancer Ther. 2016;16(1):13-20
pubmed: 26588948
Ther Adv Med Oncol. 2020 Aug 17;12:1758835920940928
pubmed: 32874208
Oncotarget. 2018 Jan 12;9(9):8584-8596
pubmed: 29492219
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1708-18
pubmed: 16985034
Cancer. 2015 Jun 1;121(11):1762-71
pubmed: 25712738
J Pathol. 2007 Oct;213(2):190-9
pubmed: 17703498
J Clin Oncol. 2017 Jun 1;35(16):1836-1844
pubmed: 28406723
Ann Saudi Med. 2015 May-Jun;35(3):196-202
pubmed: 26409793
Mod Pathol. 2016 Nov;29(11):1433-1442
pubmed: 27443512
Int J Cancer. 2016 Sep 1;139(5):1091-7
pubmed: 27082205
Genome Med. 2019 Nov 20;11(1):71
pubmed: 31747945
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Onco Targets Ther. 2019 May 14;12:3671-3682
pubmed: 31190869
Int J Colorectal Dis. 2021 Jan;36(1):117-130
pubmed: 32910207
Cancer Sci. 2017 May;108(5):853-858
pubmed: 28267224
Clin Transl Oncol. 2019 May;21(5):674-686
pubmed: 30392153
Theranostics. 2018 Jun 7;8(13):3559-3570
pubmed: 30026866
Front Immunol. 2017 Dec 04;8:1597
pubmed: 29255458
Ann Oncol. 2017 Mar 1;28(3):651-657
pubmed: 27864219
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
Front Oncol. 2019 May 14;9:396
pubmed: 31139574
Mol Diagn Ther. 2016 Apr;20(2):175-81
pubmed: 26891728
Eur J Cancer. 2013 Jun;49(9):2233-42
pubmed: 23478000
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
Mol Cancer. 2016 Aug 24;15(1):55
pubmed: 27552968
Immunotherapy. 2016;8(4):479-88
pubmed: 26973128
Mol Cancer Ther. 2014 Dec;13(12):2769-83
pubmed: 25385327
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Br J Cancer. 2019 Nov;121(10):809-818
pubmed: 31607751
Cell Commun Signal. 2019 Dec 27;17(1):173
pubmed: 31881947
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
pubmed: 18000091
Pediatr Blood Cancer. 2019 Jul;66(7):e27757
pubmed: 30977285
Cancers (Basel). 2019 Dec 11;11(12):
pubmed: 31835799

Auteurs

Abdul K Siraj (AK)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Sandeep Kumar Parvathareddy (SK)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Padmanaban Annaiyappanaidu (P)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Wael Haqawi (W)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Maha Al-Rasheed (M)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Hadeel M AlManea (HM)

Department of Pathology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Hussah F AlHussaini (HF)

Department of Pathology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Fouad Al-Dayel (F)

Department of Pathology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Khawla S Al-Kuraya (KS)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Classifications MeSH